Allergan (AGN) vs. NephroGenex (NRXGQ) Head to Head Review
Allergan (NYSE: AGN) and NephroGenex (OTCMKTS:NRXGQ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
This table compares Allergan and NephroGenex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Allergan pays an annual dividend of $2.80 per share and has a dividend yield of 1.6%. NephroGenex does not pay a dividend. Allergan pays out -12.4% of its earnings in the form of a dividend.
This is a breakdown of current ratings and recommmendations for Allergan and NephroGenex, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Allergan currently has a consensus price target of $234.82, suggesting a potential upside of 36.62%. NephroGenex has a consensus price target of $17.50, suggesting a potential upside of 624,900.00%. Given NephroGenex’s stronger consensus rating and higher probable upside, analysts plainly believe NephroGenex is more favorable than Allergan.
Volatility & Risk
Allergan has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, NephroGenex has a beta of -0.98, suggesting that its stock price is 198% less volatile than the S&P 500.
Insider and Institutional Ownership
81.3% of Allergan shares are owned by institutional investors. 0.4% of Allergan shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Allergan and NephroGenex’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Allergan||$14.57 billion||3.92||$14.97 billion||($22.59)||-7.61|
Allergan has higher revenue and earnings than NephroGenex. Allergan is trading at a lower price-to-earnings ratio than NephroGenex, indicating that it is currently the more affordable of the two stocks.
Allergan beats NephroGenex on 9 of the 13 factors compared between the two stocks.
Allergan Company Profile
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
NephroGenex Company Profile
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
Receive News & Stock Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related stocks with our FREE daily email newsletter.